In situ vaccination against mycosis fungoides by intratumoral injection of a TLR9 agonist combined with radiation: A phase 1/2 study

Blood

Volumn 119, Issue 2, 2012, Pages 355-363

  Kim, Youn H ^a   Gratzinger, Dita ^a   Harrison, Cameron ^a   Brody, Joshua D ^a   Czerwinski, Debra K ^a   Ai, Weiyun Z ^b   Morales, Anjali ^a   Abdulla, Farah ^a   Xing, Leon ^a   Navi, Daniel ^a   Tibshirani, Robert J ^c   Advani, Ranjana H ^a   Lingala, Bharathi ^a   Shah, Sumit ^a   Hoppe, Richard T ^a   Levy, Ronald ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGATOLIMOD; CD4 ANTIGEN; CD8 ANTIGEN; CD83 ANTIGEN; INTERLEUKIN 2 RECEPTOR ALPHA; PROTEIN S 100; T6 ANTIGEN; TOLL LIKE RECEPTOR 9; TOLL LIKE RECEPTOR AGONIST; TRANSCRIPTION FACTOR FOXP3;

ADULT; AGED; ANTIGEN PRESENTING CELL; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; ARTICLE; AUTOIMMUNE DISEASE; CANCER IMMUNIZATION; CANCER PATIENT; CD25+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHILL; CLINICAL ARTICLE; CONTROLLED STUDY; COUGHING; DENDRITIC CELL; DIARRHEA; DIZZINESS; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEASIBILITY STUDY; FEVER; FLU LIKE SYNDROME; HEADACHE; HEART PALPITATION; HUMAN; HUMAN TISSUE; HUMORAL IMMUNITY; IMMUNOGENICITY; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE PAIN; INJECTION SITE SWELLING; LYMPHADENOPATHY; MYALGIA; MYCOSIS FUNGOIDES; NAUSEA; NIGHT SWEAT; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; RHINITIS; SKIN NECROSIS; TREATMENT RESPONSE; TUMOR REGRESSION; VOMITING;

EID: 84862907845     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-05-355222     Document Type: Article

References (26)

1. Willemze R, Jaffe E, Burg G, et al. WHO-EORTC classification for cutaneous lymphomas. Blood. 2005;105(10):3768-3785. (Pubitemid 40656118)
2. Kim E, Hess S, Richardson S, et al. Immunopathogenesis and therapy of cutaneous T-cell lymphoma. J Clin Invest. 2005;115(4):798-812. (Pubitemid 40489380)
3. Hwang S, Janik J, Jaffe E, Wilson W. Mycosis fungoides and Sezary syndrome. Lancet. 2008;371(9616):945-957.
4. Horwitz S, Olsen E, Duvic M, Kim Y. Review of the treatment of mycosis fungoides and Sezary syndrome: a stage-based approach. J Natl Compr Canc Netw. 2008;6(4):436-442. (Pubitemid 351642616)
5. Kim Y, Duvic M, Orbitz E, et al. Clinical efficacy of zanolimumab (HuMax-CD4): two phase II studies in refractory cutaneous T-cell lymphoma. Blood. 2007;109(11):4655-4662. (Pubitemid 46827755)
6. Duvic M, Pinter-Brown L, Foss F, et al. Results of a phase 1/2 study for KW-0761, a monoclonal antibody directed against CC chemokine receptor type 4 (CCR4) in CTCL patients [abstract]. Blood. 2010;116:424a.
7. Girardi M, Berger C, Wilson L, et al. Transimmunization for cutaneous T-cell lymphoma: a phase I study. Leuk Lymphoma. 2006;47(8):1495-14503.
8. Maier T, Tun-Kyi A, Tassis A, et al. Vaccination of patients with cutaneous T-cell lymphoma using intranodal injection of autologous tumor-lysate-pulsed dendritic cells. Blood. 2003;102(7):2338-2344. (Pubitemid 37193567)
9. Geskin L, Akilov O, Butterfield L, Whiteside T, Falo L. Patient-specific dendritic cell immunization against tumor in Sezary syndrome. J Invest Dermatol. 2010;130:s56.
10. Heinzerling L, Kunzi V, Oberholzer P, Kundig T, Naim H, Dummer R. Oncolytic measles virus in cutaneous T-cell lymphomas mounts antitumor immune responses in vivo and targets interferon-resistant tumor cells. Blood. 2005;106(7):2287-2294. (Pubitemid 41510798)
11. Krieg A. Development of TLR9 agonists for cancer therapy. J Clin Invest. 2007;117(5):1184-1194. (Pubitemid 46718403)
12. Kim Y, Girardi M, Duvic M, et al. Phase I trial of a toll-like receptor 9 agonist, PF-3512676 (CPG7909), in patients with treatment-refractory, cutaneous T-cell lymphoma. J Am Acad Dermatol. 2010;63(6):975-983.
13. Li J, Song W, Czerwinski D, et al. Lymphoma immunotherapy with CpG oligodeoxynucleotides requires TLR9 either in the host or in the tumor itself. J Immunol. 2007;179(4):2493-2500.
14. Brody J, Ai W, Czerwinski D, et al. In situ vaccination with a TLR9 agonist induces systemic lymphoma regression. J Clin Oncol. 2010;28(28):4324- 4332.
15. Olsen E, Whittaker S, Kim Y, et al. Clinical endpoints and response criteria in mycosis fungoides and Sézary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas (ISCL), the United States Cutaneous Lymphoma Consortium (USCLC) and the Cutaneous Lymphoma Task Force of the European Organization for Research and Treatment of Cancer (EORTC). J Clin Oncol. 2011;29(18):2598-2607.
16. Vergier B, de Muret A, Beylot-Barry M, et al. Transformation of mycosis fungoides: clinicopathological and prognostic features of 45 cases. Blood. 2000;95(7):2212-2218. (Pubitemid 30167716)
17. Teitz-Tennenbaum S, Li Q, Okuyama R, et al. Mechanisms involved in radiation enhancement of intratumoral dendritic cell therapy. J Immunother. 2008;31(4):345-358. (Pubitemid 351595157)
18. Cummings R, Mitra S, Foster T, Lord E. Migration of skin dendritic cells in response to ionizing radiation exposure. Radiat Res. 2009;171(6):687-697.
19. Obeid M, Tesniere A, Ghiringhelli F, et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nature Med. 2007;13(1):54-61. (Pubitemid 46067386)
20. Demaria S, Bhardwaj N, McBride W, Formenti S. Combining radiotherapy and immunotherapy: a revived partnership. Int J Rad Oncol Biol Phys. 2005;63(3):655-666. (Pubitemid 41400049)
21. Lin C, Wang T, Liu C, et al. Potentiation of the immunotherapeutic effect of autologous dendritic cells by pretreating hepatocellular carcinoma with low-dose radiation. Clin Invest Med. 2008;31(3):E150-E159.
22. Berger C, Tigelaar R, Cohen J, et al. Cutaneous T-cell lymphoma: malignant proliferation of T-regulatory cells. Blood. 2005;105(4):1640-1647. (Pubitemid 40223685)
23. Gabrilovich D. Mechanisms and functional significance of tumor-induced dendritic cell defects. Nat Rev Immunol. 2004;4(12):941-952. (Pubitemid 39620069)
24. Gigante M, Blasi A, Loverre A, et al. Dysfunctional DC subsets in RCC patients: ex vivo correction to yield an effective anti-cancer vaccine. Mol Immunol. 2009;46(5):893-901.
25. Ribas A, Comin-Anduix B, Chmielowski B, et al. Dendritic cell vaccination combined with CTLA4 blockade in patients with metastatic melanoma. Clin Cancer Res. 2009;15(19):6267-6276.
26. Litzinger M, Fernando R, Curiel T, Grosenbach D, Schlom J, Palena C. IL-2 immunotoxin denileukin diftitox reduces regulatory T cells and enhances vaccine-mediated T-cell immunity. Blood. 2007;110(9):3192-3201. (Pubitemid 350106311)